National Jewish Health

Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team

Retrieved on: 
Tuesday, April 2, 2024
Professional Services, Health, Human Resources, Clinical Trials, Pharmaceutical, Biotechnology, Polyp (medicine), Organization, University, Internal medicine, Growth, UCSF, Immunotherapy, CFO, Critical Care Medicine (journal), Business, Inflammation, Patient, Roche, TSLP, Acquisition, Bryant University, MD, Senior, MBA, Biology, Asthma, Therapy, Ithaca College, National Jewish Health, Sinusitis, Eli Lilly and Company, Genzyme, Ironwood Pharmaceuticals, Babson College, Management

Upstream Bio , a clinical-stage biotech company advancing verekitug (UPB-101) for respiratory disorders, today announced strategic leadership changes including the appointment of Rand Sutherland, MD, as Chief Executive Officer.

Key Points: 
  • Upstream Bio , a clinical-stage biotech company advancing verekitug (UPB-101) for respiratory disorders, today announced strategic leadership changes including the appointment of Rand Sutherland, MD, as Chief Executive Officer.
  • “I am thrilled to join Upstream Bio as CEO.
  • By evolving and building our leadership team with these additions, we are further positioning Upstream Bio to become a leader in the immunotherapy landscape.
  • I am pleased to welcome Rand, Mike and Lisa to the Upstream Bio team.”
    Dr. Sutherland joins Upstream Bio with more than 25 years of business and clinical experience, having most recently served as CEO of Seeker Biologics, and before that as President of Translate Bio prior to its acquisition by Sanofi.

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC

Retrieved on: 
Wednesday, November 1, 2023
Principal, Gene editing, Pulmonology, VG, AAV, Pneumonitis, Aes, SVP, National Jewish Health, Valencia CF Foundation, Safety, Conference, Idiopathic pulmonary fibrosis, Inflammation, Pediatrics, MSCS, Quality of life, Disease, Clinical trial, Cystic fibrosis, Hospital, Bronchospasm, Cohort, Pharmaceutical industry, Vaccine, CFTR, Medicine

ET

Key Points: 
  • ET
    EMERYVILLE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a genetic medicines company with three novel, highly targeted next generation AAV vectors currently in human clinical studies, today announced interim data from the Phase 1/2 AEROW clinical trial evaluating aerosolized 4D-710 for treatment of cystic fibrosis lung disease.
  • Results will also be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) in both plenary and symposium sessions on November 2-3.
  • “We are pleased with the safety and tolerability of 4D-710 in participants in the AEROW study to date.
  • Initial results from the AEROW study showed that 4D-710 resulted in CFTR expression in lung airways that significantly exceeded our target profile.

MediaSource Celebrates 25 Years of PR Success and Impactful Storytelling

Retrieved on: 
Monday, September 25, 2023
Ohio State University, Business, National Jewish Health, Nationwide Children's Hospital, The Wall Street Journal, Marketing, Ohio State University Wexner Medical Center, Health care, Health equity, North, WBE, Pulse, Certification, Indian Telly Awards, Organization, Patient, The New York Times, Television, Hospital, Orlando Health, News, Social media, PR, Emmy Awards, Nursing

COLUMBUS, Ohio, Sept. 25, 2023 /PRNewswire-PRWeb/ -- Award-winning communications agency MediaSource is celebrating 25 years of PR success through impactful storytelling, unmatched media coverage for clients and industry innovations that have left an enduring mark on its community and industry.

Key Points: 
  • COLUMBUS, Ohio, Sept. 25, 2023 /PRNewswire-PRWeb/ -- Award-winning communications agency MediaSource is celebrating 25 years of PR success through impactful storytelling, unmatched media coverage for clients and industry innovations that have left an enduring mark on its community and industry.
  • President Lisa Arledge Powell founded MediaSource in Columbus, Ohio in September 1998 after a career in television news as a reporter, producer and anchor.
  • "Our commitment to impactful storytelling has always been the North Star for MediaSource," Arledge Powell said.
  • Four different MediaSource team members, including all three vice presidents, have been with the company for more than 12 years.

National Jewish Health Appoints Evan Zucker as Chair of Board of Directors

Retrieved on: 
Tuesday, September 5, 2023
National Jewish Health, Chair, Stanford University, Multimedia, Black Creek Group, Economics, Denver Zoo, Knowledge, Patient, Principal, Committee on Finance, Management, Nursing, MD

DENVER, Sept. 5, 2023 /PRNewswire/ -- Evan Zucker has been named Chair of the National Jewish Health Board of Directors.

Key Points: 
  • DENVER, Sept. 5, 2023 /PRNewswire/ -- Evan Zucker has been named Chair of the National Jewish Health Board of Directors.
  • Prior to his current position, Zucker was Partner at Ares Management Corp and Chair of the Ares Industrial Real Estate Group.
  • He joined the National Jewish Health Board in 1993 and has served in a variety of roles, including serving as the Chair of the Finance Committee for 14 years.
  • "Evan's decades of experience and knowledge of National Jewish Health will be invaluable as he assumes leadership of our Board of Directors.

Inaugural World NTM Awareness Day Marks 20-Year Anniversary and Honors Founders' Mission on August 4, 2023

Retrieved on: 
Friday, August 4, 2023
National Jewish Health, Education, Quality of life, Respiratory system, Human, Insming, NTM, Patient, Bronchiectasis, 501(c)(3) organization, Knowledge, Diagnosis, Bacteria, Nursing, Pharmaceutical industry, Fern, Research

MIAMI, Aug. 4, 2023 /PRNewswire/ -- NTM Info & Research ( www.ntminfo.org ), a pioneering global organization committed to addressing NonTuberculous Mycobacterial (NTM) and improving respiratory health, proudly announces the first-ever World NTM Awareness Day, to be held on August 4, 2023.

Key Points: 
  • MIAMI, Aug. 4, 2023 /PRNewswire/ -- NTM Info & Research ( www.ntminfo.org ), a pioneering global organization committed to addressing NonTuberculous Mycobacterial (NTM) and improving respiratory health, proudly announces the first-ever World NTM Awareness Day, to be held on August 4, 2023.
  • Nearly all NTM patients have bronchiectasis, either before or as a result of NTM.
  • "We are thrilled to announce the first World NTM Awareness Day as we commemorate our 20-year anniversary," said Leitman.
  • The inaugural World NTM Awareness Day will feature a virtual webinar and panel discussion featuring renowned experts, researchers, and advocates, providing valuable insights into the latest advancements in NTM diagnosis, treatment, and support.

Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma

Retrieved on: 
Monday, June 26, 2023
Asthma, NEA, Therapy, National Jewish Health, Patient, Safety, PEAK, Serum, Pharmaceutical industry

The trial did not meet its primary endpoint, measured by the reduction in asthma-related events.

Key Points: 
  • The trial did not meet its primary endpoint, measured by the reduction in asthma-related events.
  • This is exciting because it gives us a potential novel biomarker for treatment in patients with severe non-eosinophilic asthma, for whom new therapies are urgently needed.
  • We continue to analyze these data with our scientific advisors to inform our next steps in asthma and potentially other indications.
  • I’d like to thank the Avalo team, as well as the patients and clinical investigators for participating in this trial.”

4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting

Retrieved on: 
Wednesday, June 7, 2023
DNA, Interim, Pediatrics, CET, National Jewish Health, VG, B cell, Epithelium, Clinical trial, Quality of life, MSCS, Cystic fibrosis, Cell, RNA, Cystic fibrosis transmembrane conductance regulator, ECFS, IHC, Lung, CFTR, Biomarker, Annual general meeting, Webcast, Immunohistochemistry, Patient, CF, Conference, Fatigue, Disease, Pharmaceutical industry, Vaccine, Phosphorus, MD, Medicine

ET with cystic fibrosis specialist Dr. Jennifer L. Taylor-Cousar

Key Points: 
  • ET with cystic fibrosis specialist Dr. Jennifer L. Taylor-Cousar
    EMERYVILLE, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced positive interim clinical data from the 4D-710 Phase 1/2 AEROW clinical trial for the treatment of cystic fibrosis lung disease.
  • 4D-710 is comprised of our targeted and evolved vector, A101, and a codon-optimized CFTR∆R transgene and is designed for aerosol delivery to achieve CFTR expression within lung airway epithelial cells.
  • Interim data from the study will be presented in an oral presentation titled, “AAV mediated gene therapy for cystic fibrosis: Interim results from a Phase 1/2 clinical trial,” at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting held in Vienna, Austria on Thursday, June 8 at 5:00 p.m. CET (11:00 a.m.
  • “We believe that 4D-710 represents a potentially transformative new treatment for people with CF.

4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting

Retrieved on: 
Wednesday, May 24, 2023
Modulation, Pediatrics, CET, National Jewish Health, VG, Cohort, Epithelium, Clinical trial, MSCS, Cystic fibrosis, ECFS, AAV, CFTR, Science, Patient, Webcast, Safety, FEV1, Disease, Communications satellite, Vaccine, Pharmaceutical industry, MD, Medicine

ET

Key Points: 
  • ET
    EMERYVILLE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced an oral presentation of the interim data from the 4D-710 Phase 1/2 AEROW clinical trial for the treatment of cystic fibrosis lung disease at the European Cystic Fibrosis Society 46th Annual Meeting held in Vienna, Austria on June 7-10, 2023.
  • Clinical data will focus on safety, tolerability, pulmonary function testing (percent predicted FEV1) and respiratory-related quality of life assessments (Cystic Fibrosis Questionnaire-Revised or CFQ-R, Respiratory Domain Score).
  • The presentation will also include biomarker data on expression of the cystic fibrosis transmembrane regulator (CFTR) transgene protein from the endobronchial lung biopsies & brushings collected at week 4-8 after dosing.
  • ET to discuss the interim clinical data and provide a program update.

4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Retrieved on: 
Thursday, May 11, 2023
Pediatrics, Gene, National Jewish Health, VG, Cohort, MSCS, Cystic fibrosis, RNA, CFTR, Science, Patient, Annual general meeting, Cell, Safety, Society, FEV1, Conference, Pharmaceutical industry, Medicine

The oral presentation will be given by Jennifer L. Taylor-Cousar, M.D., MSCS, Professor, Departments of Medicine and Pediatrics, and Co-Director, Adult Cystic Fibrosis Program, Director, Cystic Fibrosis Foundation Therapeutics Development Center, National Jewish Health.

Key Points: 
  • The oral presentation will be given by Jennifer L. Taylor-Cousar, M.D., MSCS, Professor, Departments of Medicine and Pediatrics, and Co-Director, Adult Cystic Fibrosis Program, Director, Cystic Fibrosis Foundation Therapeutics Development Center, National Jewish Health.
  • In situ hybridization biomarker data, demonstrating transgene RNA expression from lung samples from Cohort 1 patients, was previously presented by Dr. Taylor-Cousar at the North American Cystic Fibrosis Conference (NACFC), November 3, 2022.
  • Additional clinical and biomarker data for Cohort 1 patients (n=3; 9-12 months follow-up) are expected to be presented at the European Cystic Fibrosis Conference in June 2023.
  • Clinical data will focus on safety, tolerability, pulmonary function testing (e.g., percent predicted FEV1) and respiratory-related quality of life assessments.

Abata Therapeutics Announces the Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Thursday, April 20, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, JDRF, Angeles volunteer association, University of Colorado School of Medicine, Drug development, University, National Jewish Health, T1D, Pediatrics, University of California, San Francisco, INVU (album), Rheumatology, CMO, Multiple sclerosis, Biomarker, Bangladesh Technical Education Board, TCR, Merck & Co., Foundation for the National Institutes of Health, MS, Science, Regulatory T cell, Third Rock Ventures, Patient, UCSF, Autoimmune disease, Lightspeed Venture Partners, Biology, Knowledge, Therapy, IND, Autoimmunity, Inflammation, Pharmaceutical industry, Nursing, Genentech

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer.

Key Points: 
  • Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer.
  • Dr. Dragone brings to Abata extensive experience in preclinical and early clinical development and autoimmune medicine.
  • I’m thrilled he’ll be joining us to advance this work.”
    Dr. Dragone most recently served as chief medical officer at Sonoma Biotherapeutics.
  • Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases.